parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.06 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in kupffer cells	0.75
chemistry Open Targets	compounds already reach it: ningetinib	0.90
trials ClinicalTrials.gov	1 Parkinson's trial, 1 stopped	0.20
literature PubMed	7 Parkinson's papers of 1,398	0.73
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 4720

receipt 4728: MERTK in dopamine neurons, braak

power: full sample +0.12 (p 0.640, n 18), 95% CI -0.37 to +0.55. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.10 (p 0.690, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.00 (p 0.997, n 18). could be the mix.
skeptic: leave-one-out range +0.03 to +0.24, sign flips 0; without severely affected donors +0.12 (p 0.640, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MERTK in dopamine neurons.

case closed: nothing better to follow up.

receipt 4727: MERTK in microglia, braak

power: full sample -0.13 (p 0.603, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.05 (p 0.847, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.06 (p 0.820, n 18). could be the mix.
skeptic: leave-one-out range -0.27 to -0.03, sign flips 0; without severely affected donors -0.13 (p 0.603, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MERTK in microglia.

case closed: nothing better to follow up.

loading the receipts